August 4, 2020
FHI Clinical is pleased to announce our partnership with Tiziana Life Sciences to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb), for the treatment of COVID-19 (SARS-CoV-2) patients.
news & events
Check out what we’ve been up to and where can we connect!
August 4, 2020
July 23, 2020
Claudia Christian of FHI Clinical recently spoke with the editor for Outsourcing-Pharma about the clinical services that FHI Clinical is providing to the Frederick National Laboratory for Cancer Research for the ongoing ACTT adaptive study allowing investigation of putative therapeutics for the treatment of COVID-19 in hospitalized adults.
FHI Clinical Inc. providing clinical operations services for ACTT-1 trial of remdesivir for treatment of COVID-19
July 14, 2020
FHI Clinical Inc. announced that it has a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT). ACTT is an adaptive study to allow investigation of putative therapeutics, for the treatment of COVID-19 in hospitalized adults.
June 25, 2020
Several months ago, FHI Clinical began recruiting scientific and technological experts to join our newly formed panel of Scientific Advisory Experts, which was created to promote best practices, build alliances and spur innovation in the clinical trials research field. Today, we are pleased to announce that we have appointed five new members.
Missed the webinar? View the recording to hear industry infectious disease experts discuss the importance of quality historical, testing and tracking data for timely, coordinated responses to outbreaks.
FHI Clinical representatives will be present at the 11th Annual SCOPE Summit in Orlando, FL, February 18-21, 2020. Set up a meeting to discuss FHI Clinical’s operational experience around the world.